Status of Leptin in MBCR-ABL p210 Positive Chronic Myeloid Leukemia Patients Before and After Imatinib Therapy: A Conflicting Scenario

Bansal, Piyush; Ghalaut, Veena Singh; Sharma, Tarun; Ps, Ghalaut; Dokwal, Sumit; Ghalaut, Ragini; Kulshrestha, Manish; Dahiya, Kiran

doi:10.7754/clin.lab.2014.140126

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevations of circulating leptin have been occasionally [ 292 ] but not universally [ 212 , 293 ] reported in AML, as well as ALL [ 212 ]. Leptin levels are also increased in CLL and CML [ 294 , 295 ] while they tend to normalize after successful imatinib treatment in CML [ 295 ]. Lower adiponectin levels are associated with adverse features in obesity such as visceral adiposity, adipose tissue inflammation, and dysmetabolism [ 12 , 296 , 297 ].…”

Section: Preventive and Therapeutic Perspectivesmentioning

confidence: 99%

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

Tsilingiris,

Vallianou,

Spyrou

et al. 2023

Curr Obes Rep

View full text Add to dashboard Cite

Purpose of Review To examine the epidemiological data on obesity and leukemia; evaluate the effect of obesity on leukemia outcomes in childhood acute lymphoblastic leukemia (ALL) survivors; assess the potential mechanisms through which obesity may increase the risk of leukemia; and provide the effects of obesity management on leukemia. Preventive (diet, physical exercise, obesity pharmacotherapy, bariatric surgery) measures, repurposing drugs, candidate therapeutic agents targeting oncogenic pathways of obesity and insulin resistance in leukemia as well as challenges of the COVID-19 pandemic are also discussed. Recent Findings Obesity has been implicated in the development of 13 cancers, such as breast, endometrial, colon, renal, esophageal cancers, and multiple myeloma. Leukemia is estimated to account for approximately 2.5% and 3.1% of all new cancer incidence and mortality, respectively, while it represents the most frequent cancer in children younger than 5 years. Current evidence indicates that obesity may have an impact on the risk of leukemia. Increased birthweight may be associated with the development of childhood leukemia. Obesity is also associated with worse outcomes and increased mortality in leukemic patients. However, there are several limitations and challenges in meta-analyses and epidemiological studies. In addition, weight gain may occur in a substantial number of childhood ALL survivors while the majority of studies have documented an increased risk of relapse and mortality among patients with childhood ALL and obesity. The main pathophysiological pathways linking obesity to leukemia include bone marrow adipose tissue; hormones such as insulin and the insulin-like growth factor system as well as sex hormones; pro-inflammatory cytokines, such as IL-6 and TNF-α; adipocytokines, such as adiponectin, leptin, resistin, and visfatin; dyslipidemia and lipid signaling; chronic low-grade inflammation and oxidative stress; and other emerging mechanisms. Summary Obesity represents a risk factor for leukemia, being among the only known risk factors that could be prevented or modified through weight loss, healthy diet, and physical exercise. Pharmacological interventions, repurposing drugs used for cardiometabolic comorbidities, and bariatric surgery may be recommended for leukemia and obesity-related cancer prevention.

show abstract

Section: Preventive and Therapeutic Perspectivesmentioning

confidence: 99%

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

Tsilingiris,

Vallianou,

Spyrou

et al. 2023

Curr Obes Rep

View full text Add to dashboard Cite

show abstract

“…23,24 The possible mechanisms underlying the relationship of overweight and obesity to the incidence of myeloma and the myelogenous leukemias are under study. 9,10,[25][26][27][28] It is unclear whether the metabolic, inflammatory, and endocrine effects of obesity, including decreased serum adiponectin, 26,28 elevated serum interleukin-6, 29 elevated serum leptin, [30][31][32][33] elevated serum insulin growth factor-1, 34,35 upregulation of the promyelocytic leukemia protein, 36 and other cytokines altered in the obese, 9 play a role in this relationship. Several of the cytokines (eg, leptin and interleukin-6), increased in obese subjects, can act directly on myeloma and myeloid cells through ligand-receptor interactions regulating proliferative rate and or apoptosis.…”

mentioning

confidence: 99%

Obesity and neoplasms of lymphohematopoietic cells

Lichtman

2016

Blood Advances

View full text Add to dashboard Cite

Role of leptin and leptin receptors in hematological malignancies

Uddin

Mohammad

2015

Leukemia & Lymphoma

View full text Add to dashboard Cite

Leptin is an adipose-derived cytokine that has an important role in bodyweight homeostasis and energy balance. There are a number of studies which have suggested that leptin and its receptors dysregulation play a critical role in the development of malignancies including hematological malignancies, mainly via activation of the JAK/STAT pathway which regulates downstream signaling pathways such as PI3K/AKT signaling and ERK1/2. In this review, current understandings of leptin/leptin receptors mediated pathogenesis in various lymphoid malignancies are described. Blocking of the leptin receptor might be a unique therapeutic approach for many hematological malignancies.

show abstract

Status of Leptin in MBCR-ABL p210 Positive Chronic Myeloid Leukemia Patients Before and After Imatinib Therapy: A Conflicting Scenario

Cited by 3 publications

References 0 publications

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

Obesity and neoplasms of lymphohematopoietic cells

Role of leptin and leptin receptors in hematological malignancies

Contact Info

Product

Resources

About